3 articles
HB Fuller Company director R. Jeffrey Bailly received 1,300 restricted stock units on September 30, 2026, converting to common stock with an expiration date of September 30, 2029.
H.B. Fuller appointed R. Jeffrey Bailly to its board to enhance medical technology expertise, aligning with a focus on higher-margin healthcare exposure while facing activist investor pressure for a s
H.B. Fuller appointed R. Jeffrey Bailly to its Board of Directors to leverage his manufacturing and medical technology expertise. The appointment supports the company's strategic shift toward higher-m
ChemBrief